What are the renal contraindications and dosing recommendations for Cafergot (ergotamine tartrate + caffeine) in patients with reduced eGFR?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cafergot Renal Contraindications

Cafergot (ergotamine tartrate + caffeine) should be used with extreme caution in patients with renal failure and is relatively contraindicated in this population due to risk of ergot toxicity and vasospastic ischemia. 1, 2

Specific Renal Contraindications

Dihydroergotamine (DHE), a related ergot derivative, explicitly lists renal impairment as a contraindication. 1 While the evidence provided does not specify an exact eGFR cutoff for Cafergot itself, the guideline data for DHE suggests that ergot alkaloids as a class should be avoided in patients with compromised renal function.

Key Contraindications for Ergot Derivatives:

  • Renal impairment is listed as a contraindication for dihydroergotamine 1
  • Renal failure is specifically mentioned as requiring extreme caution with Cafergot 2
  • Patients with peripheral vascular disease should avoid Cafergot due to vasoconstrictive effects 2

Mechanism of Concern in Renal Impairment

Ergotamine causes vasoconstriction through alpha-adrenergic agonism and interactions with prostaglandins, calcium, and serotonin, affecting both arteries and veins. 2 In patients with renal impairment:

  • Reduced drug clearance leads to accumulation and increased risk of ergot toxicity 3
  • Elimination occurs primarily through hepatic metabolism and biliary excretion, but renal dysfunction can still impair overall clearance 3
  • Vasoconstrictive effects may be exacerbated in patients with compromised renal perfusion 2

Clinical Manifestations of Ergot Toxicity

Iatrogenic ergotism can progress to fulminant necrosis and gangrene, presenting with peripheral vascular insufficiency symptoms. 2 Early warning signs include:

  • Headache, nausea, vomiting, and general malaise 4
  • Coldness and paresthesias of extremities 3
  • Muscle pains and weakness 3
  • Arterial spasm with typical angiographic patterns 2

Dosing Limitations (When Use Cannot Be Avoided)

Maximum dosing must be strictly limited to prevent toxicity: no more than 6 tablets per attack, 10 tablets per week, or 10mg ergotamine per week. 1, 3 Standard dosing for Cafergot:

  • Initial dose: 2 tablets (100mg caffeine/1mg ergotamine each) at onset 1
  • Subsequent doses: 1 tablet every 30 minutes 1
  • Maximum per attack: 6 tablets 1
  • Maximum per week: 10 tablets 1

Safer Alternatives for Migraine in Renal Impairment

Triptans are preferred over ergot derivatives for most patients and do not carry the same renal contraindications. 1 Specific options include:

  • Sumatriptan: Available in subcutaneous, intranasal, and oral forms; no renal dose adjustment required 1
  • Naratriptan: Longest half-life among triptans, may reduce recurrence 1
  • Rizatriptan: Available as absorbable wafer (Maxalt MLT) for patients with nausea 1

Critical Monitoring and Management

If ergotamine toxicity occurs, immediate discontinuation is mandatory along with cessation of cigarette smoking and caffeine. 2 Treatment approach:

  • Mild cases: Discontinuation alone may suffice 2
  • Acute severe insufficiency: Nitroprusside is the drug of choice 2
  • Less urgent situations: Prazosin has been effective 2
  • Mechanical intervention: Intra-arterial balloon dilatation may be helpful 2

Common Pitfalls to Avoid

  • Do not use Cafergot in combination with triptans - this is an absolute contraindication due to additive vasoconstrictive effects 1
  • Do not exceed weekly dosing limits - ergotamine dependence and rebound headaches are common with overuse 3, 4
  • Do not ignore early toxic symptoms - headache, nausea, and malaise may indicate impending serious toxicity 4
  • Do not use in patients already on beta blockers, antihypertensives, or SSRIs when considering DHE, as interactions increase risk 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of the acute migraine attack--current status.

Cephalalgia : an international journal of headache, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.